Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Workshop

[postponed] Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond


Speakers:
Organizers: Rebecca Elliott, Weili Yan and Surinder Kaur (Genentech)
Date: 2020-05-12- 5/12/2020
Time: 8:45-11:50 Pacific Time
Registration fee: (USD): Regular: $195; For unemployed or students: $30; Academic: $125; For major-sponsor rep (incl lunch): $0; For vendor-show rep: $35
Location: Online via Zoom
Major Sponsor: (2)KCAS Bioanalytical & Biomarker Services; Pharmaron
Vendor show vendors registered to date: (3)BioAgilytix Labs; Mercodia; MicroConstants
Registration: http://www.PBSS.org
Registration deadline:2020-09-16  (it will close sooner if the seating cap is reached)

About the Topic

Validated bioanalytical methods for the quantitative evaluation of large molecule drugs and biomarkers in a given biological matrix are critical for the successful conduct of nonclinical and clinical studies. These validated methods under regulated GxP environment provide critical data to support the safety and effectiveness of drugs and biologic products. Ligand binding assays (LBA) and emerging new technologies are widely used for regulated large molecule bioanalysis.

The workshop includes an introduction to regulated bioanalytical method development/validation and sample testing, focusing on new FDA guidance and future global harmonized guidance for large molecule bioanalysis. Applying general bioanalytical principles to emerging new technologies and/or new drug entities such as cell and gene therapy to meet health authorities’ compliance requirements will also be presented by industry recognized experts.

The following topics will be covered:

  • Introduction: Fundamentals of large molecule bioanalysis- method development, regulated validation and sample testing
  • 2018 FDA bioanalytical method validation guidance, changes from previous guidance, future global harmonized guidance
  • Hybrid LBA/LC-MS bioanalytical method
  • New technologies in large molecule bioanalysis
  • Cross validation
  • Life cycle management of bioanalytical method (critical reagents)
  • Bioanalysis in gene and/or cell therapy
  • Method transfer, validation, production from CRO perspective


2024-03-28, [In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-09-10, [In-Person] Translational PK/PD considerations and Human Dose Projection for Novel Modalities
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
©Pharmaceutical & BioScience Society, International; Last Modified: 3/18/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad